Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform

DarioHealth (NASDAQ: DRIO) reported four new studies at the American Diabetes Association Scientific Sessions showing clinical and economic signals from its digital cardiometabolic platform.

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) reported four new studies at the American Diabetes Association Scientific Sessions showing clinical and economic signals from its digital cardiometabolic platform.

Results included 0.23 fewer hospitalizations PPPY, 6.4%–14.3% 12‑month weight loss, and 44.8% of high‑risk diabetes users achieving ≥1% eA1c reduction.

Positive

• 0.23 fewer hospitalizations per patient per year versus control in high-risk members
• Prior similar utilization change associated with about $5,077 payer savings per participant per year
• 6.4% average weight loss at 12 months using Dario digital intervention alone
• 14.3% average weight loss at 12 months combining Dario with GLP-1 therapy
• 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months
• Consistent platform engagement linked with stronger weight and glycemic outcomes across conditions

Negative

• None.

Argus Jun 8 session

+0.26% close to close Open Argus

Details

News Market Reaction – DRIO

On Jun 8, the day this news came out, DRIO closed 0.26% above the previous close.

Data tracked by StockTitan Argus for the Jun 8 session.

Key Figures

ADA studies total: 27 studies Weight loss (Dario only): 6.4% weight loss Weight loss with GLP-1: 14.3% weight loss +5 more

ADA studies total

27 studies

Presented at ADA over 8 years

Weight loss (Dario only)

6.4% weight loss

At 12 months with Dario alone

Weight loss with GLP-1

14.3% weight loss

At 12 months with Dario plus GLP-1

eA1c responders

44.8% of users

High-risk diabetes users with ≥1% eA1c reduction at 12 months

Hospitalizations reduction

0.23 fewer hospitalizations PPPY

Per patient per year vs control

Payer savings link

$5,077 per participant per year

Estimated savings associated with similar utilization improvements in prior study

ADA 2026 presentations

4 studies

New data presented at ADA Scientific Sessions

Engagement duration

12 months

Time frame for weight and eA1c outcomes

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   Commercial expansion

   24h Move

   -4.5%

   Solera hypertension program expansion more than doubled addressable market.

2. May 13

   Earnings results

   24h Move

   -6.7%

   Q1 2026 revenue fell year-over-year and losses, cash burn remained significant.

3. May 04

   Earnings date notice

   24h Move

   +2.0%

   Announcement of upcoming Q1 2026 earnings call and webcast schedule.

4. Apr 20

   Clinical publication

   24h Move

   +2.8%

   Peer‑reviewed study showed improved workplace function from behavioral program.

5. Apr 13

   Board appointment

   24h Move

   +1.2%

   Appointment of experienced healthcare executive to support commercial scaling.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1, ea1c, cardiometabolic, inpatient utilization

4 terms

glp-1 medical

"14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks..."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

ea1c medical

"44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months"

eA1c stands for estimated A1c, a device-derived approximation of the laboratory HbA1c test that reflects average blood sugar over the past two to three months. Think of it as a home thermometer’s reading compared with a lab’s more precise measurement: it gives quicker, convenient feedback from continuous glucose monitors but may differ slightly from a formal lab result. Investors watch eA1c because it is commonly used as a clinical and commercial measure of how well diabetes treatments or devices control glucose, influencing regulatory outcomes, adoption, and sales.

cardiometabolic medical

"high-risk cardiometabolic populations."

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

inpatient utilization medical

"meaningful reductions in inpatient utilization among high-risk members..."

Inpatient utilization measures how much people use a hospital’s overnight services — typically tracked by number of admissions, average length of stay, and bed occupancy. For investors it signals demand, revenue potential and cost pressures: like a hotel’s occupancy rate, higher inpatient use can raise income but also strain capacity and increase operating costs, while sustained declines may signal weaker demand or shifts to outpatient care.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers 

Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone

44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months

NEW YORK, June 8, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA") Scientific Sessions highlighting the clinical and economic value of sustained engagement on its platform across high-risk cardiometabolic populations.

Taken together, the studies reinforce a clear commercial message for payers, employers and other enterprise buyers: when high-risk members stay engaged with Dario's platform, outcomes improve in ways that can translate into lower cost of care, stronger member retention and greater long-term value. Across the four studies, Dario observed meaningful reductions in inpatient utilization among high-risk members with diabetes, hypertension and obesity, strong weight outcomes with and without GLP-1 therapy, improved glycemic control and a clear link between consistent engagement and better results.

The findings support Dario's core enterprise thesis: sustained engagement in a single cardiometabolic digital platform can produce measurable clinical improvement across overlapping chronic conditions, while reducing avoidable utilization and the cost and complexity of managing multiple point solutions. The growing body of data including 27 studies presented at the ADA alone over the past eight years supports Dario's next strategic growth phase moving closer to care--demonstrating the platform's impact on clinical outcomes and positioning the Company to participate in the medical spend associated with those outcomes.

Among the findings, when compared with the control group, participants experienced 0.23 fewer hospitalizations per patient per year ("PPPY"), highlighting Dario's potential to reduce acute healthcare utilization. In a prior Dario study, similar improvements were associated with estimated payer savings of approximately $5,077 per participant per year. Additional data showed that Dario's digital health intervention alone delivered 6.4% weight loss at 12 months, while combining Dario with GLP-1 therapy produced 14.3% weight loss, exceeding real-world pharmacotherapy-only benchmarks. Dario also found that 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months, while consistent engagement predicted both weight loss and glycemic improvement.

"These studies reinforce the central promise of Dario's platform: sustained engagement can drive measurable clinical improvement in high-risk cardiometabolic populations," said Lara Dodo, Chief Operations Officer of Dario. "For enterprise buyers, the value is not just better individual outcomes. It's the ability to address diabetes, hypertension, obesity and weight management through one integrated platform rather than a fragmented set of point solutions."

"What stands out across all four studies is the consistency of the signal," said Yifat Hershcovitz, PhD, VP Clinical & Scientific Affairs at Dario. "Whether the focus is utilization, weight or glycemic control, the data show that members who stay meaningfully engaged can achieve important improvements. That reinforces the value of combining personalized digital support, connected monitoring and coaching in a way that helps sustain healthy behaviors over time."

The four presentations further underscore Dario's platform approach to cardiometabolic care. Dario's core capabilities include its AI-driven engagement engine, connected devices and personalized human coaching, which together are designed to support sustained behavior change across diabetes, hypertension and weight management. For enterprise customers, the findings also strengthen the case for solutions that can deliver measurable outcomes across overlapping chronic conditions rather than addressing each condition in isolation.

Strategic highlights include:

• High-risk population impact: Demonstrated inpatient-utilization improvement in members with diabetes, hypertension and obesity
• Economic relevance: Findings support the potential for avoided admission costs and broader payer savings
• Weight-management performance: Strong 12-month weight outcomes both as a standalone digital intervention and in combination with GLP-1 therapy
• Engagement differentiation: Consistent engagement predicted stronger clinical outcomes, reinforcing Dario's platform design and long-term habit-building model
• Cardiometabolic breadth: Evidence of value across multiple related conditions and outcome categories within a single platform

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential clinical and economic benefits of the Company's platform; the potential for sustained engagement to improve clinical outcomes, reduce healthcare utilization and lower cost of care; the potential for payer savings and member retention benefits; the expansion of its revenue model toward claims-based and outcomes-driven reimbursement opportunities; the Company's ability to participate in value-based healthcare arrangements; the scalability and effectiveness of its cardiometabolic platform; the benefits of its AI-driven engagement engine, connected devices and personalized coaching; and the Company's growth, commercialization and future revenue opportunities. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/dario-presents-four-studies-at-american-diabetes-association-scientific-sessions-highlighting-commercial-and-clinical-value-of-its-digital-health-platform-302793052.html

SOURCE DarioHealth Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DarioHealth (NASDAQ: DRIO) announce at the June 2026 ADA Scientific Sessions?

DarioHealth announced four studies at the June 2026 ADA Scientific Sessions demonstrating clinical and economic signals from its digital cardiometabolic platform. According to Dario, the data highlight reduced inpatient utilization, meaningful weight loss, improved glycemic control, and benefits tied to sustained member engagement across high-risk populations.

What were the key clinical results from DarioHealth's DRIO digital platform studies at ADA 2026?

The studies reported reduced hospitalizations, significant weight loss, and improved glycemic control for high-risk users. According to Dario, members showed 0.23 fewer hospitalizations per patient per year and 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months.

How much weight loss was achieved with DarioHealth's DRIO platform, with and without GLP-1 therapy?

DarioHealth reported 6.4% weight loss at 12 months using its platform alone and 14.3% when combined with GLP-1 therapy. According to Dario, these 12‑month outcomes exceeded real-world pharmacotherapy-only benchmarks and were observed alongside engagement-driven improvements in other cardiometabolic measures.

How do DarioHealth's ADA 2026 findings relate to potential cost savings for payers?

The new studies showed 0.23 fewer hospitalizations per patient per year versus control, indicating possible cost avoidance. According to Dario, a prior study linked similar utilization improvements to estimated payer savings of about $5,077 per participant per year, suggesting economic relevance alongside clinical outcomes.

What did DarioHealth reveal about engagement and outcomes in its DRIO cardiometabolic platform?

DarioHealth reported that consistent engagement on its cardiometabolic platform predicted stronger clinical outcomes across weight and glycemic control. According to Dario, sustained use of its AI-driven tools, connected devices, and coaching supported long-term behavior change in diabetes, hypertension, obesity, and weight management populations.

How many DarioHealth studies have been presented at the American Diabetes Association meetings?

DarioHealth stated that 27 of its studies have been presented at American Diabetes Association meetings over eight years. According to Dario, this growing body of evidence supports its strategy to move closer to care and participate in medical spend linked to measured outcomes.

What is the strategic significance of DarioHealth's ADA 2026 results for DRIO enterprise customers?

The results support a model focused on outcomes-based and claims-linked payments for enterprise buyers. According to Dario, demonstrating reduced utilization and multi-condition improvements strengthens the case for a single cardiometabolic digital platform serving health plans, employers, and other organizations managing overlapping chronic conditions.